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Background: Triple-negative breast cancer (TNBC) is a rather aggressive form of breast 
cancer, comprised by early metastasis formation and reduced overall survival of the affected 
patients. Steroid hormone receptors and the human epidermal growth factor receptor 2 are 
not overexpressed, limiting therapeutic options. Therefore, new treatment options have to be 
investigated. The aim of our preliminary study was to detect coherences between some molecules 
of intracellular signal transduction pathways and survival of patients with TNBC, in order to 
obtain some hints for new therapeutical solutions.
Methods: Thirty-one paraffin-embedded tumor tissue samples, which were determined to be 
negative for steroid hormone receptors as well as human epidermal growth factor receptor 2, 
were immunohistochemically stained for a number of signal transduction molecules from 
several signaling pathways. β-Catenin, HIF1α, MCL, Notch1, LRP6, XBP1, and FOXP3 
were stained with specific antibodies, and their staining was correlated with patient survival 
by Kaplan–Meier analyses.
Results: Only two of the investigated molecules have shown correlation with overall survival. 
Cytoplasmic staining of HIF1α and centro-tumoral lymphocyte FOXP3 staining showed statisti-
cally significant correlations with survival.
Conclusion: The coherence of signal transduction molecules with survival of patients with 
TNBC is still controversially discussed in the literature. Our study comprises one more mosaic 
stone in the elucidation of these intracellular processes and their influences on patient outcome. 
Lots of research still has to be done in this field, but it would be worthwhile as it may offer new 
therapeutic targets for a group of patients with breast cancer, which is still hard to treat.
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Introduction
Breast cancer is still a prevalent malignant disease worldwide, and the most frequent 
cause of death in women.1 Although lethality has decreased over the last 40 years, still 
30% of the affected patients die from the consequences of breast cancer.2
“Triple-negative breast cancer” (TNBC) is pathologically defined by a low or 
almost absent expression of estrogen receptor, progesterone receptor, and human 
epidermal growth factor receptor 2 (Her2).3,4 This aggressive form of breast cancer 
often affects rather young women and is accompanied by a frequent development of 
visceral metastases, a high risk of recurrence, and a reduced overall survival (OAS) 
independent of tumor size, staging, and lymph node affection.5,6 The low expression 
of hormone receptor and Her2 receptor also restricts the possibilities of treatment 
options in a manner that TNBCs are treated postoperatively with a dose-dense or 
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metronome chemotherapy using platin or anthracycline 
and taxan containing chemotherapy and radiation.7 New 
therapeutic strategies using poly-ADP-ribose-polymerase or 
vascular endothelial growth factor inhibitors, in fact, increase 
survival time but have strong side effects.8–11
Therefore, there is a further need of new therapeutical 
strategies, targeting inter- and intracellular signal trans-
duction pathways, regulating cell adhesion and prolifera-
tion. One of those signal transduction cascades could be 
the Notch1 pathway, which plays a role in normal breast 
development and cell fate determination and is, especially 
in TNBC, activated in an aberrant manner. An inhibition 
of this pathway had been shown to result in an antitumor 
activity by cell cycle arrest, apoptosis, and disruption of 
angiogenesis.12,13 HIF1α is also a member of the Notch-
signaling cascade, associated with a poor prognosis for 
the affected patients by promoting carcinoma onset and 
formation of lung metastasis. A reduction of expression 
resulted in reduced primary tumor growth, suppression of 
lung metastasis, and prolonged survival.14 Together with 
XBP1, HIF1α forms a transcriptional complex that is 
responsible for onset of tumorigenicity. An inhibition of 
XBP1 results in reduced tumor growth, giving hints that it 
could be used as a therapeutic target.15 Another signal trans-
duction pathway, which might be of therapeutical interest, 
is the Wnt/β-catenin pathway, as it regulates cell cycle, cell 
growth, and tumor progression, and seems to be responsible 
for poor clinical outcomes. An inhibition of Wnt receptor is 
already known for its therapeutical use, as it induces LRP6 
degradation.16 LRP6 does not seem to have a correlation 
with estrogen receptor, progesterone receptor, and Her2, 
but its use as a drug target receptor significantly prolonged 
survival time in a mouse model.17 MCL1, another signal 
molecule within the Wnt/β-catenin pathway, modulates 
mitochondrial physiology and is associated with enhanced 
metastasis formation and decreased disease-free survival 
(DFS) and could also be of therapeutic interest.18 A tran-
scription factor, which is highly expressed in tumor cells, 
is FOXP3, a potent repressor of several oncogenes, which 
could be a target for new therapeutical interventions of 
TNBC. It is involved in TNBC susceptibility and prognosis, 
but the prognosis is dependent on the cellular localization 
of FOXP3.19 If it is found in the cytoplasm, it is a marker 
for poor OAS, but if it is found in the nucleus, OAS is 
markedly improved.20
We show here a correlation of these signal transduc-
tion molecules with survival of patients with TNBC in 
a retrospective analysis of survival data combined with 
immunohistochemical staining of tissue samples.
Materials and methods
Patient samples
Tissue samples of breast cancer patients, who were treated 
between 2001 and 2002 at the Department of Obstetrics and 
Gynaecology of Ludwig Maximilians University of Munich, 
were collected and embedded in paraffin in the Department 
of Pathology of Ludwig Maximilians University of Munich 
(ethical votes compliant to the Declaration of Helsinki: 
LMU 048-08 and 148-12) and written informed consent 
was obtained. Hormone receptor status and Her2 status were 
determined pathologically. Thirty-one samples were regarded 
as TNBC. The patients who donated these samples had an 
average age of 62 years. Tumor samples were further clas-
sified as shown in Table 1.
Table 1 Patient/tumor characteristics of the tissue samples used for immunohistochemical staining
Regarded trait Number of patients per class
Tumor size pT1 pT2 pT3 pT4 pTx
19 8 1 2 1
lymph node affection pn0 pn1 pn2 pnx
17 11 2 1
Metastatic stage pM0 pM1 pMx
20 1 10
grading g1 g2 g3 gx
1 7 14 9
histology Ductal lobular Medullar Other
18 4 7 2
Patient management Operation chemotherapy radiation hormonal therapy
31 8 22 2
Patient outcome Disease progression recurrence not recorded
5 8 18
survival ,1 year $5 years $10 years .10 years
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impact of signal transduction molecules on breast cancer survival
immunohistochemical staining
The paraffin-embedded tissue samples were cut by sliding 
microtome and transferred onto specially covered microscope 
slides (SuperFrost Plus; Menzel GmbH, Berlin, Germany). The 
slides were air-dried overnight at 56°C–58°C. For immunohis-
tochemistry, paraffin was removed by a 20-minute incubation 
of the slides in Xylol (Merck, Darmstadt, Germany) and sub-
sequent washes in different dilutions of ethanol (100%, 90%, 




 in methanol 
(VWR International, Radnor, PA, USA) to prevent unspecific 
staining of tissue samples. To reconstitute the antigens, slides 
were washed first in ethanol (100%, 70%, 50%) and afterward 
in water, and boiled in 0.1 M Na citrate (Merck) buffer (pH 6) 
for 5 minutes. The slides were cooled down and then washed 
in water and twice in phosphate-buffered saline (Biochrom, 
Cambridge, UK). To prevent unspecific binding of the primary 
antibody, samples are blocked in 10% normal goat serum 
(Vector Laboratories, Burlingame, CA, USA) for 20 minutes, 
blocking solution was removed, and primary antibodies were 
applied in the appropriate concentrations (Table 2).
Incubation of primary antibodies was carried out at 4°C 
for 18 hours. Slides were washed with phosphate-buffered 
saline and incubated with the biotinylated secondary antibody, 
which is included in the staining kit (Vector Laboratories), for 
30 minutes at room temperature. Thereafter, the samples were 
treated with avidin and biotinylated horseradish peroxidase 
(ABC) reagent (Vector Laboratories) for 30 minutes, and 





 was added to the slides for 1 minute. Enzyme reaction 
was stopped by washing the slides in water. Nuclei were 
then counterstained by Hemalaun (Applichem, Darmstadt, 
Germany) for 5 minutes before slides were again dehydrated 
by ethanol (70%, 96%, 100%) and xylol and embedded in 
Eukitt (Medite, Burgdorf, Germany).
To be sure of antibody function and to determine optimal 
dilutions, positive and isotype controls were carried out.
Microscopy
Staining of the samples was observed and evaluated by two 
independent persons by a Leitz Diaplan light microscope 
(Ernst Leitz GmbH, Wetzlar, Germany) (Figure 1). Evalua-
tion was carried out following the Immune Reactive Score 
(IRS), calculated from staining intensity and number of 
stained cells.21 The IRS is then set into reference to survival 
data.
statistical evaluation
Statistical analysis was performed by SPSS (SPSS Inc., 
Chicago, IL, USA) version 22.0. Survival curves were gener-
ated by Kaplan–Meier analysis. Cutoff values for statistical 
analysis were set in reference to the median of IRS staining, 
thereby dividing the patient samples in similar groups.
Results
Different molecules, which play a role in signal transduction 
cascades, were stained immunohistochemically in tissue 
sections of patients with TNBC. Via Kaplan–Meier analy-
sis, correlations between staining and patient survival were 
investigated. A statistically significant correlation could be 
found for only two signaling molecules: HIF1α staining of 
the cytoplasm (C) and FOXP3 staining of lymphocytes in 
the center of the tumor tissue (CT; P=0.004 and P=0.015, 
respectively). For a nuclear (N) HIF1α staining and FOXP3 
staining of lymphocyte clusters in peritumoral regions (TLS) 
and of the tumor itself (Tum), no correlations were found 
(P=0.934, P=0.230, and P=0.433). All further investigated 
molecules, which contribute to intracellular signal transduc-
tion, did not show any statistically significant coherences 
with survival (Figure 2 and Table 3).
Discussion and conclusion
The results presented in our rather preliminary study are in 
part compliant with former research results, but there are 
some contrasts as well. HIF1α staining was already found 
to have a correlation with survival and was furthermore 
regarded as a poor prognostic factor for survival of breast 
cancer patients.22,23 With the immunohistochemical staining, 
we could reassure this finding, especially when cytoplasmic 
HIF1α is regarded. That means, the coherence between 
HIF1α and survival is dependent on the intracellular 
Table 2 Primary antibodies used for staining
Antibody Clonality Working dilution Distributor
anti-hiF1α Monoclonal rabbit-igg 1:2,000 sigma aldrich
anti-β-catenin Polyclonal rabbit-igg 1:300 Diagnostic Biosystems
anti-XBP1 Monoclonal rabbit-igg 1:400 sigma aldrich
anti-FOXP3 Monoclonal mouse igg1 1:300 abcam
anti-notch1 Monoclonal mouse-igg 1:100 sigma aldrich
anti-Mcl1 Monoclonal rabbit-igg 1:1,000 abcam
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localization of this molecule, a finding which has not yet 
been published. β-Catenin is an important signaling mol-
ecule in the development of TNBC, but no data on its role 
in patient survival were published so far.24 This finding was 
confirmed by our results. MCL1 in contrast is shown to be 
involved in enhanced metastasis formation and decreased 
DFS of patients with TNBC, and also for Notch1, a role 
in TNBC survival was shown recently.18 Cao et al found 
Figure 1 staining of triple-negative breast cancer tissue with antibodies against molecules of different signal transduction cascades.
Notes: Blue: nuclear counterstain by hemalaun; brown: ABC staining of the respective signal transduction molecule. Magnification is 25 times.
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that Notch1 is significantly correlated with lymph node 
status, a worse OAS, and DFS, and is an indicator of a poor 
prognosis.25 With the results we obtained from staining of 
a small number of TNBC tissue samples, we were not able 
to reassure these findings.
For LRP6 and XBP1, there are, at least up to now, no data 
available concerning their influence on survival of patients 
with TNBC. Some clues are found in the literature anyway, 
in order to elucidate the role of these two signal transduction 
molecules in survival of affected patients. LRP6 is known 
to stimulate tumor growth, and its inhibition was shown 
to suppress tumor growth in vivo, so it could be presumed 
that an overexpression of LRP6 has a negative influence on 
OAS, but on the other hand, it had been shown recently that 
LRP6 expression is inversely correlated with metastasis 
in mouse and human breast cancer, concluding that LRP6 
could be used as a therapeutical target to prevent metastasis 
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support the latter finding. A certain function of XBP1 in 
TNBC survival was shown in coherence with the inducible 
nitric oxide synthase pathway, as inducible nitric oxide syn-
thase inhibitors impaired, among others, endoplasmatic stress 
pathways, represented by IRE1α and XBP1. This impairment 
significantly reduced tumor growth and metastasis forma-
tion.28 However, no direct correlation between XBP1 and 
OAS is described until now, and our data also indicate that 
there is no coherence.
Again, in accordance with our results are the data 
published for FOXP3 as a marker for poor prognosis in breast 
cancer survival.29 More in detail, no prognostic significance 
was found for FOXP3 expression in tumor cells and patient 
survival, but FOXP3-positive lymphocytes were significantly 
associated with a poor OAS.
As a conclusion, it can be stated that signal transduction 
pathways are the upcoming targets for a new therapeutical 
option in the treatment of TNBC, but still lots of research is 
necessary to clarify the role of such signal transduction mol-
ecules and to find out which are the most suitable for cancer 
treatment. In our special case, it would mean to apply the 
technique of immunohistochemical staining of tissue samples 
with subsequent retrospective analysis of patient follow-up 
to a higher number of samples, to increase statistical 
significance and thereby to reinforce our findings.
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